Turing Pharma seeks CEO to replace Shkreli, plans job cuts
NEW YORK] Turing Pharmaceuticals said on Tuesday it is seeking a new chief executive to replace Martin Shkreli, the price-gouging entrepreneur who is facing US charges of securities fraud, and will cut jobs in a restructuring.
The private Swiss-based company will also expand its board to include new, independent members, it added.
Shkreli, 32, resigned as CEO on Friday, a day after his arrest on charges that he had engaged in a Ponzi-like scheme. He pleaded not guilty and was released on US$5 million bail.
On Monday, KaloBios Pharmaceuticals said Shkreli was "terminated" as CEO and had resigned from the board.
Turing did not specify the number of job cuts in a statement. It could not be immediately reached for comment. "These staff changes put us in the best position to continue executing on our long-term plan," said Chairman and Interim Chief Executive Ron Tilles, who took over Shkreli's job on Friday.
Shkreli gained notoriety when, as Turing's CEO, he raised the price of a life saving drug overnight to US$750 from US$13.50.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sony deal for Paramount would draw added regulatory scrutiny
Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom